How are energy investors positioned?
Investing.com -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) stock rose 2.4% following the company’s update on its development product portfolio, highlighting progress in its lead product for Netherton Syndrome and other rare skin disease treatments.
The late clinical stage specialty pharmaceutical company reported that its lead product, QRX003 for Netherton Syndrome, is advancing in two pivotal registrational clinical studies across sites in the US, Europe, and the Middle East. The company aims to complete recruitment for these studies by early to mid-first quarter of 2026, with plans to file for regulatory approval in the second half of 2026.
QRX003 is positioned to potentially become the first approved treatment for Netherton Syndrome. Quoin intends to self-commercialize the product in the US, Western Europe, and Japan, while leveraging nine commercial partnerships covering 61 additional countries for global distribution upon approval.
The company also shared positive initial data from its Peeling Skin Syndrome clinical study in New Zealand, reporting clinically meaningful improvements across key endpoints. This represents the first known clinical findings for this disease, which currently has no approved treatments. Quoin plans to expand this study to include an additional 4 to 6 subjects.
Additionally, Quoin’s topical rapamycin program, developed in partnership with University College Cork in Ireland, continues to progress toward clinical testing anticipated in the first half of 2026. The program targets rare skin diseases including microcystic lymphatic malformations, venous malformations, and angiofibromas.
As part of its portfolio optimization, Quoin has discontinued the development of QRX007 for Netherton Syndrome and QRX004 for Epidermolysis Bullosa to focus resources on its more promising programs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.